Long-term follow-up shows epcoritamab drives deep, durable responses in relapsed/refractory follicular lymphoma (R/R FL)

被引：0
|
作者：
Izutsu, K. [1 ]
Akahane, D. [2 ]
Toubai, T. [3 ]
Saito, T. [4 ]
Mishima, Y. [5 ]
Fujisaki, T. [6 ]
Kitawaki, T. [7 ]
Kumode, T. [8 ]
Suehiro, Y. [9 ]
Ishitsuka, K. [10 ]
Conlon, R. [11 ]
Noguchi, H. [12 ]
Buchbjerg, J. [13 ]
Favaro, E. [13 ]
Fukuhara, N. [14 ]
机构：
[1] Natl Canc Ctr, Dept Hematol, Tokyo, Japan
[2] Tokyo Med Univ, Dept Hematol, Tokyo, Japan
[3] Yamagata Univ, Div Hematol & Cell Therapy, Fac Med, Yamagata, Japan
[4] Aichi Canc Ctr Hosp, Dept Hematol & Cell Therapy, Nagoya, Aichi, Japan
[5] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Hematol Oncol, Tokyo, Japan
[6] Matsuyama Red Cross Hosp, Japan Red Cross Soc, Dept Hematol, Matsuyama, Ehime, Japan
[7] Kyoto Univ Hosp, Dept Hematol & Oncol, Kyoto, Japan
[8] Kindai Univ, Dept Hematol & Rheumatol, Osaka, Japan
[9] Natl Hosp Org Kyushu Canc Ctr, Dept Hematol & Cell Therapy, Fukuoka, Japan
[10] Kagoshima Univ Hosp, Dept Hematol & Rheumatol, Kagoshima, Japan
[11] AbbVie, N Chicago, IL USA
[12] Genmab KK, Tokyo, Japan
[13] Genmab AS, Copenhagen, Denmark
[14] Tohoku Univ, Dept Hematol, Sendai, Miyagi, Japan
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.07.548
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO20-2
引用
收藏
页码：S1337 / S1337
页数：1
相关论文
共 50 条
  • [21] Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma
    Wang, Michael
    Rule, Simon
    Zinzani, Pier Luigi
    Goy, Andre
    Casasnovas, Olivier
    Smith, Stephen D.
    Damaj, Gandhi
    Doorduijn, Jeanette K.
    Lamy, Thierry
    Morschhauser, Franck
    Panizo, Carlos
    Shah, Bijal D.
    Davies, Andrew
    Eek, Richard
    Dupuis, Jehan
    Jacobsen, Eric
    Kater, Arnon P.
    Gouill, Steven L. E.
    Oberic, Lucie
    Robak, Tadeusz
    Dua, Richa
    Frigault, Melanie M.
    Izumi, Raquel
    Nguyen, Dorothy
    Patel, Priti
    Yin, Ming
    Jurczak, Wojciech
    BLOOD, 2018, 132
  • [22] Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma
    L Giaccone
    M Festuccia
    F Zallio
    R Sorasio
    L Brunello
    E Maffini
    C Dellacasa
    R Passera
    G Iovino
    S Aydin
    M Boccadoro
    U Vitolo
    N Mordini
    M Pini
    A Busca
    B Bruno
    Bone Marrow Transplantation, 2017, 52 : 1208 - 1211
  • [23] Long-Term Follow-Up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma
    Wang, Michael
    Rule, Simon
    Zinzani, Pier Luigi
    Goy, Andre
    Casasnovas, Oliver
    Smith, Stephen
    Damaj, Gandhi
    Doorduijn, Jeanette K.
    Lamy, Thierry
    Morschhauser, Franck
    Panizo, Carlos
    Shah, Bijal
    Davies, Andrew
    Eek, Richard
    Dupuis, Jehan
    Jacobsen, Eric
    Kater, Arnon P.
    Le Gouill, Steven
    Oberic, Lucie
    Robak, Tadeusz
    Dua, Richa
    Frigault, Melanie M.
    Izumi, Raquel
    Nguyen, Dorothy
    Patel, Priti
    Yin, Ming
    Jurczak, Wojciech
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S316 - S316
  • [24] Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial.
    Friedberg, Jonathan W.
    Younes, Anas
    Fisher, David C.
    Gordon, Leo I.
    Moore, Joseph O.
    Czuczman, Myron S.
    Miller, Thomas P.
    Stiff, Patrick J.
    Cheson, Bruce D.
    Forero-Torres, Andres
    McKinney, Byron
    Leonard, John P.
    BLOOD, 2008, 112 (11) : 369 - 370
  • [25] Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up
    Rule, Simon
    Dreyling, Martin H.
    Goy, Andre
    Hess, Georg
    Auer, Rebecca
    Kahl, Brad S.
    Angel Hernandez-Rivas, Jose
    Qi, Keqin
    Deshpande, Sanjay
    Parisi, Lori
    Wang, Michael L.
    BLOOD, 2019, 134
  • [26] Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up
    Villasboas, Jose. C.
    Kim, Tae Min
    Taszner, Michal
    Novelli, Silvana
    Cho, Seok-Goo
    Merli, Michele
    Ubieto, Ana Jimenez
    Tessoulin, Benoit
    Poon, Michelle
    Walewski, Jan
    Yi, Shuhua
    Song, Yuqin
    Chong, Geoffrey
    Luminari, Stefano
    Bachy, Emmanuel
    Guidez, Stephanie
    Alonso, Aranzazu
    Jagadeesh, Deepa
    Zhang, Wei
    Magnano, Laura
    Iskierka-Jazdzewska, Elzbieta
    Tani, Monica
    Cai, Jessica
    Uppala, Amulya
    Shariff, Saleem
    Chi, Lei
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth
    Tucker, David
    BLOOD, 2023, 142
  • [27] Subcutaneous epcoritamab with rituximab plus lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.
    Falchi, Lorenzo
    Leppa, Sirpa
    Wahlin, Bjorn E.
    Nijland, Marcel
    Christensen, Jacob Haaber
    De Vos, Sven
    Holte, Harald
    Linton, Kim M.
    Abbas, Aqeel
    Wang, Liwei
    Dinh, Minh
    Elliott, Brian
    Belada, David
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL).
    Jacobson, Caron Alyce
    Hemmer, Michael T.
    Hu, Zhen-Huan
    Frank, Matthew Joshua
    Popplewell, Leslie
    Ahmed, Nausheen
    Lin, Yi
    Best, Timothy
    Beygi, Sara
    Miao, Harry H.
    Fu, Christine
    Sun, Fang
    Xu, Hairong
    Pasquini, Marcelo C.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Primary Clinical Response of Relmacabtagene Autoleucel in Adults with Relapsed/Refractory Follicular Lymphoma (r/r FL) in China
    Song, Yuqin
    Ying, Zhitao
    Yang, Haiyan
    Guo, Ye
    Li, Wenyu
    Zou, Dehui
    Wu, Jianqiu
    Yang, Su
    Zhang, Pian
    Ma, Meilin
    Zhou, Zisong
    Zheng, Hongxia
    Zhu, Jun
    BLOOD, 2021, 138
  • [30] Efficacy Outcomes of Treatments for Double Relapsed/Refractory Follicular Lymphoma (R/R FL): A Systematic Literature Review
    Kahl, Brad S.
    Patel, Anik R.
    Zaidi, Omer
    Snedecor, Sonya J.
    Purdum, Anna G.
    BLOOD, 2020, 136
12345